Results 11 to 20 of about 6,497 (208)
Diagnostic Accuracy of Prostatic Specific Antigen Densityin Different Prostatic Disorders
Pakistan Armed Forces Medical Journal, 2022 Objective: To determine the diagnostic accuracy of PSA density in Prostate Cancer, Benign Prostatic Hyperplasia (BPH) and Prostatitis, taking biopsy as the gold standard. Study Design: Cross-sectional study.
Qamar Bashir +5 more
doaj +1 more source
Asian Journal of Andrology, 2022 The goal of this study was to investigate the clinical application of free/total prostate-specific antigen (F/T PSA) ratio, considering the new broad serum total PSA (T-PSA) “gray zone” of 2.0–25.0 ng ml−1 in differential diagnosis of prostate cancer ...
Xue-Dan Gao +7 more
doaj +1 more source
Body mass index in relation to prostate-specific antigen-related parameters
BMC Urology, 2021 Background Only a few previous studies conducted to assess the association between body mass index (BMI) and prostate-specific antigen (PSA) related parameters have taken prostate volume (PV) and blood volume (BV) into consideration.
Dandan Lin +3 more
doaj +1 more source
Oncology Reviews, 2020 Prostate-specific antigen velocity (PSAV) is widely used to detect PC and predict its progression. In this study, we qualitatively synthesized the currently available evidence from published studies regarding the PSAV role in PC.
Arslaan Javaeed +3 more
doaj +1 more source
The Efficiency of the Serum Prostate Specific Antigen Levels in Diagnosing Prostatic Enlargements [PDF]
Journal of Clinical and Diagnostic Research, 2013 Background: The objective of this study was to evaluate the serum PSA levels in patients presenting with enlarged prostate and to evaluate the efficiency of serum PSA to diagnose and differentiate benign and malignant enlargements.
Ingle SP, Ingle Ramona, Sukesh
doaj +1 more source
Complexed Prostate-specific Antigen and the “Prostate-specific Antigen Gap” [PDF]
Clinical Chemistry, 1999 Jung et al. (1) reported an apparent gap between total serum prostate-specific antigen (t-PSA) and the sum of free PSA (f-PSA) plus α1-antichymotrypsin-PSA (ACT-PSA) in patients with prostate carcinoma (PCa) but not in those with benign prostatic hypertrophy (BPH).
Iain S Ross +5 more
openaire +1 more source
Prostate Specific Antigen [PDF]
American Journal of Clinical Pathology, 2006 Prostate cancer is a highly prevalent disease that is characterized by a wide range of aggressiveness, ranging from the clinically irrelevant to the rapidly progressive, lethally metastatic. Since its introduction as a serum test in the late 1980s, prostate-specific antigen (PSA) has been increasingly promulgated as an important biomarker for prostate ...
Kristin R. Swanson +2 more
+5 more sources
CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
Jurnal Urologi Indonesia, 2016 Objective: In Hasan Sadikin General Hospital Bandung prostate biopsy is recommended for patients with prostate specific antigen (PSA) levels above 10 ng/mL or PSA density (PSAD) above 0.15 if PSA in between 4–10 ng/mL.
Daniel Simanjuntak, Ferry Safriadi
doaj +1 more source
Prostate International, 2013 Racial differences exist in the incidence of prostate cancer (PCa). Although many studies have looked at the performance of prostate-specific antigen (PSA) and PSA density (PSAD) in the detection of PCa, only a few have looked at it in relation to ...
Ahmad Anies Shahab +5 more
doaj +1 more source
PROSTATE-SPECIFIC ANTIGEN VELOCITY AND REPEATED MEASURES OF PROSTATE-SPECIFIC ANTIGEN
Urologic Clinics of North America, 1997 Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer.
H B, Carter, J D, Pearson
openaire +2 more sources